FDA Panel Reviews Data Showing Merck’s COVID-19 Antiviral Reduces Hospitalization by 30 Percent

Merck’s COVID-19 antiviral, molnupiravir, lowered the risk of hospitalization or death by just 30 percent, according to the results of a late-stage study that will be reviewed today by an FDA expert panel.
Source: Drug Industry Daily